Clinical Research Directory

Inclusion Criteria: 1. Is ≥18 years of age at the time of signature of the main study ICF. 2. Has an ECOG PS of 0 or 1. 3. Has loss of the MTAP gene, documented by a validated assay 4. Has one of the following disease characteristics: * 1L or 2L metastatic PDAC * Locally advanced, recurrent or metastatic NSCLC (no more than 2 prior lines of therapy) with documented KRAS mutation at G12X or G13X locally obtained via an analytically validated assay (Dose expansion only). 5. Has evidence of measurable disease based on RECIST v1.1. 6. Adequate organ function Exclusion Criteria: 1. Has received prior treatment with a PRMT5 inhibitor, MAT2A inhibitor or RAS inhibitor. 2. Has an active infection requiring systemic therapy. 3. Any condition that may impact the ability to take or absorb study drugs 4. Has known or suspected active or untreated CNS metastases associated with progressive neurological symptoms